High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer

We report the results of high-dose chemotherapy (HDC) with peripheral blood stem cell transplantation in twenty-one patients with primarily advanced or relapsed ovarian cancer. Twenty-five women underwent stem cell collection, and 21 were finally treated with different regimens of HDC containing cyc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2001-04, Vol.127 (4), p.243-250
Main Authors: BOJKO, Peter, SCHEULEN, Max Ernst, HILGER, Ralf, OBERHOFF, Carsten, SCHINDLER, Adolf Eduard, SEEBER, Siegfried
Format: Article
Language:English
Subjects:
Adult
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Combined Modality Therapy
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Female
Hematopoietic Stem Cell Transplantation
Humans
Medical sciences
Middle Aged
Ovarian cancer
Ovarian Neoplasms - therapy
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the results of high-dose chemotherapy (HDC) with peripheral blood stem cell transplantation in twenty-one patients with primarily advanced or relapsed ovarian cancer. Twenty-five women underwent stem cell collection, and 21 were finally treated with different regimens of HDC containing cyclophosphamide, etoposide, carboplatin, and treosulfan. The patients received cyclophosphamide +/- cisplatin and cisplatin + paclitaxel, respectively, followed by G-CSF (n = 24) or GM-CSF (n = 1) for stem cell mobilization. A mean of 7.2 +/- 6.1 x 10(6) CD34+ cells per kg bw were collected. Thirteen patients received double transplants and one patient received a triple transplant. The median age was 47 years (range 24-61 years) and the mean number of prior regimens was three (range 1-8). Engraftment occurred on time in all patients and there was one treatment-related death resulting in an overall mortality rate of 4.8% among the 21 patients treated with HDC. The response rate was 72% (48% CR, 24% PR) and the mean time to progression and overall survival after HDC were 7 and 32 months, respectively. HDC could be performed safely in patients with advanced ovarian cancer. However, even with a high response rate, the duration of response is short, warranting new treatment approaches to further improve the outcome of this population of patients with unfavorable prognosis.
ISSN:0171-5216
1432-1335
DOI:10.1007/s004320000202